Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21136924 | 1.00 | AHCY (0.43) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL21136229 | 1.00 | AHCY (0.43) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL22224906 | 1.00 | AHCY (0.43) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL21136252 | 1.00 | AHCY (0.43) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL22224959 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL21136919 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL22224825 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL21136219 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL22224580 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP | |
| SCHEMBL22224961 | 0.94 | CYP3A4 (0.42) | AHCYCYP3A4CYP2C9BTN3A1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4088725-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF A VIRUS FROM THE PICORNAVIRIDAE FAMILY | ATEA Pharmaceuticals, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | AHCY 721/4885CYP3A4 2535/4885CYP2C9 4118/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | AHCY 689/4885CYP3A4 2594/4885CYP2C9 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.